LncRNA BCAR4 promotes colon cancer progression via activating Wnt/&#x03B2;-catenin signaling

Shurui Ouyang; Xinbin Zheng; Xin Zhou; Zhengquan Chen; Xuefeng Yang; Ming Xie

doi:10.18632/oncotarget.21590

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

LncRNA BCAR4 promotes colon cancer progression via activating Wnt/β-catenin signaling

Shurui Ouyang, Xinbin Zheng, Xin Zhou, Zhengquan Chen, Xuefeng Yang and Ming Xie _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:92815-92826. https://doi.org/10.18632/oncotarget.21590

Metrics: PDF 3078 views | HTML 2914 views | ?

Abstract

Shurui Ouyang1, Xinbin Zheng1, Xin Zhou1, Zhengquan Chen1, Xuefeng Yang1 and Ming Xie1

1Gastrointestinal Department, Affiliated Hospital of Zunyi Medical College, Guizhou 563000, China

Correspondence to:

Ming Xie, email: [email protected]

Keywords: BCAR4, colon cancer, proliferation, Wnt/β-catenin

Received: August 01, 2017 Accepted: September 04, 2017 Published: October 06, 2017

ABSTRACT

BCAR4 (Breast Cancer Anti-Estrogen Resistance 4) is a long noncoding RNA that was identified as an oncogene in breast cancer. In our research, we found that the expression level of BCAR4 was upregulated in colon cancer tissues compared to paired normal tissues. What’s more, higher BCAR4 expression was correlated with lower survival rate in patients with colon cancer. Mechanistically, we showed that BCAR4 activated Wnt/β-catenin signaling in colon cancer by protecting β-catenin from degradation. We also showed that BCAR4 overexpression promoted cell proliferation and migration in colon cancer. However, silencing BCAR4 inhibited cell growth and promoted apoptosis. Besides, BCAR4 knockdown decreased tumor growth in vivo. These findings indicate that BCAR4 facilitated colon cancer progression by enhancing cell proliferation and inhibiting apoptosis via BCAR4/β-catenin axis. BCAR4 may be a useful new target for treatment of patients with colon cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21590

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

LncRNA BCAR4 promotes colon cancer progression via activating Wnt/β-catenin signaling

Abstract